Development and characterization of itraconazole-loaded solid lipid nanoparticles for ocular delivery

Pharmaceutical Development and Technology

Volumn 20, Issue 4, 2015, Pages 458-464

  Mohanty, Biswaranjan ^a   Majumdar, Dipak K ^b   Mishra, Sagar K ^c   Panda, Amulya K ^d   Patnaik, Soma ^d  

^a SEEMANTA INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

^b UNIVERSITY OF DELHI   (India)

^c UTKAL UNIVERSITY   (India)

^d NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Itraconazole; Palmitic acid; Permeation; Solid lipid nanoparticles; Stearic acid

Indexed keywords

ITRACONAZOLE; PALMITIC ACID; POLYVINYL ALCOHOL; SOLID LIPID NANOPARTICLE; STEARIC ACID; ANTIFUNGAL AGENT; DRUG CARRIER; EMULSION; NANOPARTICLE; STEARIC ACID DERIVATIVE;

ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; APPARENT PERMEABILITY; ARTICLE; ASPERGILLUS FLAVUS; CORNEA EDEMA; CORNEA PERMEABILITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EMULSION; FEASIBILITY STUDY; IN VITRO STUDY; INHIBITION ZONE; LOW TEMPERATURE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; THERMAL ANALYSIS; TOPICAL OCULAR DELIVERY; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION; ZETA POTENTIAL; ANIMAL; ASPERGILLOSIS; CHEMISTRY; CORNEA; DRUG EFFECTS; DRUG FORMULATION; GOAT; INTRAOCULAR DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; X RAY DIFFRACTION;

ADMINISTRATION, OPHTHALMIC; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FLAVUS; CHEMISTRY, PHARMACEUTICAL; CORNEA; DRUG CARRIERS; DRUG COMPOUNDING; EMULSIONS; GOATS; ITRACONAZOLE; NANOPARTICLES; PALMITIC ACID; PARTICLE SIZE; STEARIC ACIDS; X-RAY DIFFRACTION;

EID: 84929406416     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2014.882935     Document Type: Article

References (35)

1. Johns KJ, O'Day DM. Pharmacologic management of keratomycosis. Surv Ophthalmol 1988;33:178-188.
2. O'Day DM. Selection of appropriate antifungal therapy. Cornea 1987;6:238-245.
3. Jones DB. Decision making in the management of microbial keratitis. Ophthalmology 1981;88:814-820.
4. Forster RK. The cornea scientific foundation and clinical practice. Boston, MA: Little Brown & Co; 1987:228-240.
5. Richardson K, Brammer KW, Marriott MS. Activity of UK49, 858, a bis-triazole derivative against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother 1985;27:832-835.
6. Dupont B, Drouhet E. Early experience with itraconazole in vitro and in patients. Pharmacokinetic studies and clinical results. Rev Infect Dis (Suppl) 1987;9:S71-S76.
7. Davies N. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol 2000;27:558-562.
8. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm 2000;50:161-177.
9. Muller RH, Souto EB, Radtke M. Nanostructured lipid carriers. A novel generation of solid lipid drug carriers. Pharm Technol Eur 2005;17:45-50.
10. Ravi Kumar MN. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci 2000;3:234-258.
11. Muller RH, Maassen S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nano-particles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996;4:161-170.
12. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011;12:62-76.
13. Yuan H, Huang LF, Du YZ, et al. Solid lipid nanoparticles prepared by solvent diffusion method in a nanoreactor system. Colloids Surf B Biointerfaces 2008;61:132-137.
14. Xie S, Zhu L, Dong Z, et al. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B Biointerfaces 2011;83: 382-387.
15. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006;29: 278-287.
16. Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv 2010;17:467-489.
17. Malhotra M, Majumdar DK. In vitro transcorneal permeation of ketorolac tromethamine from buffered and unbuffered aqueous ocular drops. Indian J Exp Biol 1997;35:941-947.
18. Venkateswarlu V, Manjunath K. Preparation characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004;95:627-638.
19. Hao J, Fang X, Zhou Y, et al. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomed 2011;6: 683-692.
20. Silverman RB. The organic chemistry of drug design and drug action. New York (NY): Elsevier; 2004:55-61.
21. Rowe RC, Sheskey PJ, Owen SC. Handbook of pharmaceutical excipients. 5th ed. Somerset: Butler & Tanner; 2006:308-310.
22. Siekmann B, Westesen K. Submicron sized parentral carrier systems based on solid lipids. Pharm Pharmacol Lett 1992;1:123-126.
23. Varshosaz J, Minayian M, Moazen E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J Liposome Res 2010;20:115-123.
24. Abdelwahed W, Degobert G, Fessi H. A pilot study of freeze-drying of poly (epsilon-caprolactone) nanocapsules stabilized by poly (vinyl alcohol): formulation and process optimization. Int J Pharm 2006;309:178-188.
25. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008;127: 97-109.
26. Heiati H, Tawashi R, Shivers RR, Phillipps NC. Solid lipid nanoparticles as drug carriers. I. Incorporation and retention of the lipophilic prodrug 30-azido-30-deoxythymidine palmitate. Int J Pharm 1997;146:123-131.
27. Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 2007;337:299-306.
28. Liu J, Gong T, Wang C, et al. Solid lipid nanoparticles loaded with insulin by sodium cholatephosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm 2007;340: 153-162.
29. Walstra P. Encyclopedia of emulsion technology. 4th ed. Becher P, ed. New York: Marcel Dekker; 1996:1-62.
30. Huang ZR, Hua SC, Yang YL, Fang JY. Development and evaluation of lipid naoparticles for camptothecin delivery: A comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin 2008;29: 1094-1102.
31. Yuan H, Miao J, Du YZ, et al. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm 2008;348:137-145.
32. K. Westesen. Particles with modified physico-chemical properties, their preparation and uses, US Patent 6; 2001, 197, 349.
33. Li Y, Dong L, Jia A, et al. Preparation and characterization of solid lipid nanoparticles loaded traditional Chinese medicine. Int J Biol Macromol 2006;38:296-299.
34. Maurice DM, Riley MV. Ocular pharmacokinetics. In: Graymore CN, ed. Biochemistry of the eye. London: Academic Press; 1970:6-16.
35. Schoenwald RD, Huang HS. Corneal penetration behavior of betablocking agents. I. Physicochemical factors. J Pharm Sci 1983;72: 1266-1272.